General information:
Substance group: Antiepileptic ATC: N03AF01
Trade names: Carbamazepin*®, Carbaflux®, Carbagamma®, Finlepsin®, Tegretal®, Timonil®, Espa-Lepsin®
available doses: tablets 200 / 400 mg, retard pills 150 / 200 / 300 / 400 / 600 mg, suspension
for oral 20 mg/mL
Reference ranges:
4-12 mg/L
Toxic Plasma levels: >20 mg/L
Pharmacokinetics
T1⁄2 : 11-13 h (Combination therapy: 6–10 h) (metabolite: 12-60 h)
Tmax: 8.5 h (1.72 – 12 h) (retard: 12 h)
Bioavailability: 60 – 85%
Protein binding: 70 – 80% (metabolite: 48 – 53%)
Clearance: 30 mL/min (long-term therapy: 90 mL/min)
Excretion: Urine: 72%; Faeces: 28%
Metabolism: hepatic
Distribution volume: 0.8 – 1.9 L/kg KG
Time to steady state: 2 – 8 days
Sampling :
Material: Serum (Monovette brown) Minimum volume for analysis: 500µL
Recommendation: trough level (directly before the next intake)
Requirement (internal): about Orbis requirement (external):
Analytics:
Test principle: High-performance liquid chromatography with UV detection (HPLC-UV)
Liquid-liquid extraction with ether, chromatographic separation, absorption measurement
Analysis system: HPLC
Findings release: on the same working day, via LIMS
Indication:
Level 2: TDM recommended
TDM at least every 3-6 months or more frequently in case of dose titration, suspected non-adhesion, dose changes, changes in comedic eradication, adverse drug effects, insufficient clinical improvement.
Determination of the therapeutic dose by determining the plasma levels and depending on the effectiveness.
DrugBank: https://go.drugbank.com/drugs/DB00564